Personalized app for melanoma survivorship care
Personalised Survivorship Care for Patients With Melanoma: A Multicenter Randomised Controlled Trial of the Survivorship Care Plan App
NA · Erasmus Medical Center · NCT06643286
This study is testing a new app designed to help people with stage I and II melanoma manage their care better and feel more empowered compared to those who receive standard care.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 180 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Erasmus Medical Center (other) |
| Locations | 4 sites (Dordrecht, South Holland and 3 other locations) |
| Trial ID | NCT06643286 on ClinicalTrials.gov |
What this trial studies
This multicenter randomized controlled trial evaluates the effectiveness of the Digizorg Melanoma Survivorship Care Plan app for patients diagnosed with stage I and II melanoma. A total of 180 participants will be randomized to receive either the app or usual care, with the app providing tailored healthcare information based on their specific melanoma stage and needs. The study will assess patient empowerment, satisfaction with information and care, and healthcare utilization through questionnaires and medical records over a 12-month period. Additionally, the process of app uptake and implementation will be evaluated through interviews and log-data analysis.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have received a primary diagnosis of cutaneous melanoma stage I or II within the last 0-4 months.
Not a fit: Patients with stage III or IV melanoma, or those who do not speak Dutch sufficiently, may not benefit from this study.
Why it matters
Potential benefit: If successful, this app could enhance patient empowerment and satisfaction in melanoma survivorship care.
How similar studies have performed: Other studies have shown promise in using digital tools for personalized patient care, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years or older * Patients who have received a primary diagnosis of cutaneous melanoma stage I to II in the past 0-4 months Exclusion Criteria: * Patients with irresectable stage III melanoma, patients receiving neo-adjuvant treatment and patients with stage IV melanoma. * Patients who do not have (sufficient) command of the Dutch language.
Where this trial is running
Dordrecht, South Holland and 3 other locations
- Albert Schweitzer hospital — Dordrecht, South Holland, Netherlands (RECRUITING)
- Erasmus MC — Rotterdam, South Holland, Netherlands (RECRUITING)
- Franciscus Gasthuis & Vlietland hospital — Rotterdam, South Holland, Netherlands (NOT_YET_RECRUITING)
- Maasstad hospital — Rotterdam, South Holland, Netherlands (RECRUITING)
Study contacts
- Study coordinator: Marjolein Lugtenberg, PhD
- Email: m.lugtenberg@erasmusmc.nl
- Phone: +31614448940
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Melanoma, Melanoma, Stage II, Stage I, Melanoma Stage, Survivorship, Survivorship care, Application, RCT